Chronic fluoxetine treatment alters cardiovascular functions in unanesthetized rats  by Crestani, Carlos C. et al.
European Journal of Pharmacology 670 (2011) 527–533
Contents lists available at SciVerse ScienceDirect
European Journal of Pharmacology
j ourna l homepage: www.e lsev ie r .com/ locate /e jpharCardiovascular Pharmacology
Chronic ﬂuoxetine treatment alters cardiovascular functions in unanesthetized rats
Carlos C. Crestani a, Rodrigo F. Tavares b, Franscisco S. Guimarães b, Fernando M.A. Correa b,
Sâmia R.L. Joca c,⁎, Leonardo B.M. Resstel b,⁎⁎
a Department of Natural Active Principles and Toxicology, School of Pharmaceutical Sciences of Araraquara, São Paulo State University, UNESP, SP, 14801–902, Brazil
b Department of Pharmacology, School of Medicine of Ribeirão Preto, USP, SP, 14049–900, Brazil
c Department of Physics and Chemistry, School of Pharmaceutical Sciences of Ribeirão Preto; USP, Ribeirão Preto, SP, 14040–903, Brazil⁎ Correspondence to: S. Joca, Department of Phys
Pharmaceutical Sciences of Ribeirão Preto, Ribeirão
Tel.: +55 16 36024705; fax: +55 16 3602 4880.
⁎⁎ Correspondence to: L. Resstel, Department of Pharm
Ribeirão Preto, University of São Paulo, Ribeirão Preto, S
16 3602 0441; fax: +55 16 3301 6980.
E-mail addresses: samia@usp.br (S.R.L. Joca), leoress
(L.B.M. Resstel).
0014-2999© 2011 Elsevier B.V.
doi:10.1016/j.ejphar.2011.09.030
Open access under the Elsea b s t r a c ta r t i c l e i n f oArticle history:
Received 24 May 2011
Received in revised form 6 September 2011
Accepted 11 September 2011
Available online 19 September 2011
Keywords:
Chronic ﬂuoxetine treatment
Hypertension
Arterial pressure
Heart rate
Baroreﬂex
Psychological stressIn the present study, we investigated the effects induced by ﬂuoxetine treatment (10 mg/kg) for either 1 or
21 consecutive days on arterial pressure and heart rate basal levels, baroreﬂex activity, hemodynamic
responses to vasoactive agents and cardiovascular responses to acute restraint stress. Mild hypertension
was observed after 21 days of treatment, but not after administration for 1 day. Moreover, chronic treatment
affected the baroreﬂex control of heart rate, which was characterized by a reduced reﬂex tachycardia and an
enhanced bradycardiac baroreﬂex response. The pressor responses to systemic administration of the selec-
tive α1-adrenoceptor agonist phenylephrine, as well as the depressor responses to systemic infusion of the
nitric oxide donor sodium nitroprusside, were reduced after chronic ﬂuoxetine treatment. Fluoxetine treat-
ment for 21 days reduced both the pressor and tachycardiac responses evoked by acute restraint stress. In
conclusion, the results indicate the development of mild hypertension after chronic ﬂuoxetine treatment.
This effect was followed by changes in the baroreﬂex control of heart rate and altered vascular responsive-
ness to pressor and depressor agents, which may explain, at least in part, the increase in arterial pressure.
Chronic ﬂuoxetine treatment also affected cardiovascular responses to restraint stress, thus indicating that
ﬂuoxetine may affect cardiovascular adaptation under conditions of stress.ics and Chemistry, School of
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Fluoxetine and other selective serotonin reuptake inhibitors
(SSRIs) have achieved such a phenomenal level of use mainly because
of a supposed favorable safety and tolerability proﬁle over tricyclic
antidepressants (Gram, 1994). However, evidence suggests that
SSRIs are associated with cardiovascular side effects (Pacher and
Kecskemeti, 2004). Most notably, reports of arrhythmias, electrocar-
diogram abnormalities and rest bradycardia have been documented
with the use of these substances (Ravina et al., 1998; Roose et al.,
1998; Spier and Frontera, 1991). Moreover, the co-administration of
ﬂuoxetine and other drugs that interact with the serotoninergic sys-
tem has been associated with the serotonin syndrome, which consists
of a triad of symptoms including behavioral changes and autonomic
instability (Radomski et al., 2000). This evidence of cardiovascular
toxicity is further reinforced by in vitro studies demonstrating that
ﬂuoxetine, as well other SSRIs, affect membrane potentials and ionchannels in cardiac and vascular cells (Pacher and Kecskemeti,
2004; Ungvari et al., 2000). Although these data indicate cardiovascular
side effects associated with ﬂuoxetine treatment, the actions of this drug
on cardiovascular functions are not yet completely understood.
It has been described that impairment of baroreﬂex activity is
associated with a number of cardiovascular diseases, such as heart
failure, myocardial infarction and hypertension (Deck et al., 1992;
Grassi et al., 2006; Osculati et al., 1990). Although the importance of
the baroreﬂex in the control of cardiovascular activity has been
shown, information regarding the effect of SSRIs on baroreﬂex
activity are limited (Alper, 1992; Mofﬁtt and Johnson, 2004).
The impairment of vascular reactivity to vasoactive agents has been
proposed as an indicator of atherosclerosis (Harrison et al., 1987), and is
related to the pathogenesis of hypertension (Panza et al., 1993; Resstel
et al., 2006). Therefore, cardiovascular complications following ﬂuoxe-
tine treatment may be associated with changes in vascular reactivity.
Indeed, in vitro studies have suggested that ﬂuoxetine affects vascular
reactivity to vasoconstrictor agents (Pacher et al., 1999; Ungvari et al.,
1999). However, there is no evidence in vivo of the effect of ﬂuoxetine
treatment on vascular responsiveness to vasoactive agents.
Cardiovascular changes are part of the physiological response
aimed to maintain homeostasis during exposure to stressful aversive
situations (Ulrich-Lai and Herman, 2009). This adaptive mechanism is
characterized by increases in arterial pressure and heart rate (Resstel
et al., 2008). Although some studies have investigated the effect of
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the results are contradictory (Grippo et al., 2006; Roche et al.,
2007). Differences in the stressor employed and treatment duration
may explain these contradictory results (McDougall et al., 2005).
In addition, none of the aforementioned studies investigated the
mechanisms responsible for the cardiovascular effects induced by
ﬂuoxetine in stressed and non-stressed animals.
So, in the present study, we investigated the effect of acute or
multiple (i.e., daily for 21 consecutive days) systemic ﬂuoxetine treat-
ment on arterial pressure and heart rate basal levels, the baroreﬂex
activity, and the hemodynamic responses to vasoactive agents in
conscious rats; as well as in the cardiovascular responses elicited by
an acute restraint stress.
2. Material and methods
2.1. Animals
Experimental procedures were carried out following protocols
approved by the Ethical Review Committee of the School of Medicine
of Ribeirão Preto, which complies with the Guiding Principles for
Research Involving Animals and Human Beings of the American
Physiological Society. Wistar rats weighing 250–260 g at the begin-
ning of the experiments were used in the present experiments.
Animals were housed in plastic cages in a temperature-controlled
room at 25 °C in the Animal Care Unit of the Department of Pharma-
cology, School of Medicine of Ribeirão Preto, University of São Paulo.
They were kept under a 12:12 h light–dark cycle (lights on between
6:00 am and 6:00 pm) and had free access to water and standard
laboratory food.
2.2. Fluoxetine treatment
Animals were randomly divided into four groups: (i) chronic vehicle
(n=9), daily intraperitoneal (i.p.) injections of vehicle (saline+0.2%
Tween-80, 1 ml/kg) for 21 days; (ii) chronic ﬂuoxetine (n=10), daily
i.p. injections of ﬂuoxetine (10 mg/kg) for 21 days; (iii) acute vehicle
(n=8), a single injection of vehicle (saline+0.2% Tween-80,
1 ml/kg); and (iv) acute ﬂuoxetine (n=7), a single injection of ﬂuoxe-
tine (10 mg/kg) (Alper, 1992; Lino-de-Oliveira et al., 2001). Animals
submitted to acute treatmentwere left undisturbed, except for cleaning
the cages, in the Animal Care Unit for the same period as animals
submitted to chronic treatments.
2.3. Surgical preparation
Twenty-four hours before the trial, rats were anesthetized with
tribromoethanol (250 mg/kg, i.p.) and a catheter (a 4 cm segment of
PE-10 heat-bound to a 13 cm segment of PE-50, Clay Adams, Parsippany,
NJ, USA) was inserted into the abdominal aorta through the femoral
artery, for arterial pressure and heart rate recording. A second catheter
was implanted into the femoral vein for the infusion of vasoactive agents
to evoke arterial pressure changes. Both catheters were tunnelled under
the skin and exteriorized on the animal's dorsum. After the surgery, rats
were treated with a streptomycin and penicillin polyantibiotic formula-
tion (0.27 mg/kg, i.m.; Pentabiotico®; Fort Dodge, Brazil), to prevent
infection, and received the non-steroidal anti-inﬂammatory drug ﬂunixin
meglumine (0.025mg/kg, i.m.; banamine®; Schering Plough, Brazil) for
postoperative analgesia.
2.4. Measurement of cardiovascular parameters
On the day of the experiment, the arterial cannula was connected
to a pressure transducer and the pulsatile arterial pressure was
recorded using an HP-7754A pre-ampliﬁer (Hewlett Packard, Palo
Alto, CA, USA) and an acquisition board (MP100A, Biopac SystemsInc, Goleta, CA, USA) connected to a personal computer. Mean arterial
pressure, systolic arterial pressure, diastolic arterial pressure, and
heart rate values were derived from pulsatile arterial pressure
recordings.
2.5. Baroreﬂex assessment
The baroreﬂex was tested by intravenous infusion of either the
selective α1-adrenoceptor agonist phenylephrine (50 μg/ml/kg at
0.32 ml/min/kg) or the nitric oxide donor sodium nitroprusside
(70 μg/ml/kg at 0.8 ml/min/kg), using an infusion pump (K.D. Scien-
tiﬁc, Holliston, MA, USA) (Crestani et al., 2010; Head and McCarty,
1987; Resstel et al., 2006). Phenylephrine and sodium nitroprusside
caused incremental pressor or depressor responses, respectively.
Infusions of vasoactive drugs were randomized and lasted for 30–40 s,
resulting in the injection of a total dose of 8–10 μg/kg of phenylephrine
and 20–25 μg/kg of sodium nitroprusside.
2.6. Method of baroreﬂex evaluation
Baroreﬂex curves were constructed matching mean arterial
pressure variations with heart rate responses. Paired values of mean
arterial pressure (ΔMAP) and heart rate (ΔHR) variations were plotted
to create sigmoid curves for each rat, which were used to determine
baroreﬂex activity (Head and McCarty, 1987). Baroreﬂex analysis
using sigmoid curves were characterized by four parameters: (i) P1
(bpm) lower heart rate plateau and P2 (bpm) upper plateau;
(ii) heart rate range (bpm), i.e. difference betweenupper and lower pla-
teau levels; (iii) median blood pressure (BP50, mm Hg), which is the
mean arterial pressure at 50% of the heart rate range; and (iv) average
gain (G, bpm/mmHg), which is the average slope of the curves between
+1 and−1 standard derivations fromBP50. To analyze bradycardic and
tachycardic responses separately, heart rate values matching 10, 20, 30
and 40 mm Hg of mean arterial pressure changes were calculated.
Values were plotted to create linear regression curves for each rat and
their slopes were compared to test changes in baroreﬂex gain.
2.7. Dose–response mean arterial pressure curves
The graded rises and falls in mean arterial pressure evoked respec-
tively by increasing concentrations of phenylephrine and sodium
nitroprusside produced by intravenous infusions were used to gener-
ate dose–response curves. In this manner, it was possible to generate
dose–response curves that demonstrated the effect of ﬂuoxetine
treatment on pressor and depressor responsiveness. Dose–effect
curves were generated for each vasoactive agent using mean arterial
pressure values corresponding to cumulative recording times (each
5 s) after starting the infusion. The maximal effect (Emax) and the
dose at 50% of the mean arterial pressure range (ED50) for each vaso-
active agent were compared in all experimental groups.
2.8. Acute restraint stress
Animals were submitted to restraint by placing each rat in a plastic
cylindrical restraint tube (diameter¼6.5 cm, length¼15 cm), ventilat-
ed by holes (1 cm diameter) that comprised approximately 20% of the
tube surface. Restraint lasted 60 min, afterwhich the ratswere returned
to their home cages. Each rat was submitted to one session of restraint
in order to avoid habituation.
2.9. Drugs
Phenylephrine hydrochloride ((R)-(−)-1-(3-hydroxyphenyl)-2-
methylaminoethanol hydrochloride) (Sigma, St. Louis, MO, USA),
sodium nitroprusside dihydrate (Na2[Fe(CN)5NO]·2H2O; Sigma),
and tribromoethanol (Br3CCH2OH; Sigma) were dissolved in saline
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Tween-80. Flunixin meglumine (Banamine®, Schering Plough, Brazil)
and poly-antibiotic preparation of streptomycins and penicillins
(Pentabiotico®, Fort Dodge, Brazil) were used as provided.
2.10. Experimental procedures
Animals were transferred to the experimental room in their home
box. They were allowed 60 min to adapt to experimental room condi-
tions such as sound and illumination before starting arterial pressure
and heart rate recording. The experimental room was temperature
controlled (25 °C) and was acoustically isolated from the other
rooms. Constant background noise was generated by an air exhauster
to minimize sound interference within the experimental room.
Animals in the groups for chronic vehicle (n=9) and chronic
ﬂuoxetine (n=10) received the 21st injection of their treatments,
whereas those in the groups for acute vehicle (n=8) and acute ﬂuox-
etine (n=7) were treated with vehicle (i.p., 1 ml/kg) and ﬂuoxetine
(i.p., 10 mg/kg), respectively. Thirty min later, phenylephrine and
sodium nitroprusside were randomly infused. Subsequently, animals
were restrained for 60 min, after which they were returned to their
home cages.
2.11. Data analysis
Data were expressed as means±S.E.M. The basal values of arterial
pressure and heart rate for each treatment, the Emax and ED50 of the
mean arterial pressure responses caused by vasoactive agents, as
well as the baroreﬂex parameters of linear and nonlinear curves
were compared using two-way ANOVA with treatment regimen
(acute or chronic) and treatment (vehicle or ﬂuoxetine) as indepen-
dent factors. When interactions between the factors were observed,
groups were compared using Bonferroni's post hoc test. Nonlinear
regression analysis was also used to compare mean arterial pressure
changes caused by vasoactive drugs. Time-course curves of mean
arterial pressure and heart rate changes to acute restraint stress
were compared using three-way ANOVA with treatment regimenFig. 1. Effect of acute or chronic (21 day) treatment with vehicle or ﬂuoxetine on mean art
and heart rate (HR). The bars represent the mean±S.E.M. *Pb0.05 vs chronic vehicle, two
signiﬁcantly increased basal parameters of systolic (Pb0.01), diastolic (Pb0.01) and meanand treatment as independent factors, and time as repeated measure-
ment. When interactions between the factors were observed, groups
were compared using Bonferroni's post hoc test. Results of statistical
tests with Pb0.05 were considered signiﬁcant.
3. Results
3.1. Effect of acute or chronic ﬂuoxetine treatment on arterial pressure,
heart rate, and body weight
There were signiﬁcant effects of treatment regimen (SAP: F(1,30)=
23, Pb0.0001; DAP: F(1,30)=29, Pb0.0001; MAP: F(1,30)=27,
Pb0.0001) and treatment (SAP: F(1,30)=32, Pb0.0001; DAP: F(1,30)=
23, Pb0.0001; MAP: F(1,30)=39, Pb0.0001), as well as treatment regi-
men×treatment interaction (SAP: F(1,30)=12, Pb0.005; DAP: F(1,30)=
18, Pb0.0002; MAP: F(1,30)=20, Pb0.0001) on systolic, diastolic, and
mean arterial pressure baseline values (Fig. 1 and Table 1). Post hoc
analyses indicated that ﬂuoxetine treatment for 21 days, but not acute
administration (SAP: PN0.05; DAP: PN0.05; and MAP: PN0.05), signiﬁ-
cantly increased systolic (Pb0.01), diastolic (Pb0.01) and mean
(Pb0.01) arterial pressure. Analyses of resting heart rate did not indi-
cate effects of either treatment regimen (F(1,30)=0.1, PN0.05) or treat-
ment (F(1,30)=0.15, PN0.05) (Fig. 1 and Table 1).
3.2. Effect of acute or chronic ﬂuoxetine treatment in baroreﬂex control of
heart rate
Nonlinear regression analysis of baroreﬂex activity indicated that
ﬂuoxetine treatment for 21 days affected P1 and P2 plateau, and
BP50 (Fig. 2 and Table 2). There were signiﬁcant effects of treatment
regimen (P1: F(1,30)=38, Pb0.0001; P2: F(1,30)=47, Pb0.0001;
BP50: F(1,30)=50, Pb0.0001) and treatment (P1: F(1,30)=29,
Pb0.0001; P2: F(1,30)=23, Pb0.0001; BP50: F(1,30)=42, Pb0.0001),
as well as treatment regimen×treatment interaction (P1: F(1,30)=
11, Pb0.005; P2: F(1,30)=41, Pb0.0001; BP50: F(1,30)=33, Pb0.0001).
Post hoc analyses revealed that ﬂuoxetine treatment for 21 days, but
not acute administration (P1: PN0.05; P2: PN0.05; and BP50: PN0.05),erial pressure (MAP), systolic arterial pressure (SAP), diastolic arterial pressure (DAP),
-way ANOVA followed by Bonferroni's post hoc test. Fluoxetine treatment for 21 days
(Pb0.01) arterial pressure.
Table 1
Values of body weight, mean arterial pressure (MAP), systolic arterial pressure (SAP),
diastolic arterial pressure (DAP) and heart rate (HR) obtained from acute vehicle
(n=8), acute ﬂuoxetine (n=7), chronic vehicle (n=9), and chronic ﬂuoxetine
(n=10) rats. Value is the mean±S.E.M.
Group Body weight
(g)
MAP
(mm Hg)
SAP
(mm Hg)
DAP
(mm Hg)
HR
(bpm)
Acute vehicle 415±8 98±1 120±2 78±2 352±6
Acute ﬂuoxetine 412±6 102±3 124±3 79±3 353±8
Chronic vehicle 415±10 99±2 122±2 80±1 359±8
Chronic ﬂuoxetine 378±5a 118±2a 139±3a 97±3a 355±8
a Pb0.05 vs chronic vehicle, two-way ANOVA followed by Bonferroni's post hoc test.
Table 2
Parameters derived from sigmoidal baroreﬂex curves obtained from acute vehicle
(n=8), acute ﬂuoxetine (n=7), chronic vehicle (n=9), and chronic ﬂuoxetine
(n=10) rats. Value is the mean±S.E.M.
Group G
(bpm/mm Hg)
P1
(bpm)
P2
(bpm)
HR range
(bpm)
BP50
(mm Hg)
Acute vehicle −1.1±0.05 −40±3 70±3 109±5 −6±1
Acute ﬂuoxetine −1.2±0.05 −46±2 74±5 118±6 −5±2
Chronic vehicle −1.2±0.1 −48±4 69±1 117±4 −4±2
Chronic vehicle −0.9±0.1 −74±2a 40±1a 114±2 12±1a
a Pb0.05 vs chronic vehicle, two-way ANOVA followed by Bonferroni's post hoc test.
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(Pb0.001) (Fig. 2 and Table 2). Analyses of heart rate range and gain
did not indicate signiﬁcant effects of either treatment regimen (heart
rate range: F(1,30)=0.2, PN0.05; gain: F(1,30)=3, PN0.05) or treatment
(heart rate range: F(1,30)=0.5, PN0.05; gain: F(1,30)=3, PN0.05)
(Fig. 2 and Table 2).
The effect of arterial pressure increases or decreases on heart rate
were analyzed separately using linear regression (Fig. 2B). Analyses
of bradycardiac response slopes (acute vehicle: −1.2±0.2 bpm/mm
Hg; acute ﬂuoxetine: -1.4±0.1 bpm/mm Hg; chronic vehicle: −1.3±
0.1 bpm/mm Hg; chronic ﬂuoxetine:−2.3±0.1 bpm/mm Hg) indicat-
ed signiﬁcant effects of treatment regimen (F(1,30)=14, Pb0.0005)
and treatment (F(1,30)=21, Pb0.0001), as well as treatment regi-
men×treatment interaction (F(1,30)=9, Pb0.005). Post hoc analyses
revealed that ﬂuoxetine treatment for 21 days (Pb0.001), but not
acute administration (PN0.05), signiﬁcantly increased reﬂexFig. 2. (A) Sigmoid baroreﬂex curve correlating mean arterial pressure change (ΔMAP)
and heart rate response (Δ HR) of acute vehicle (n=8) (○, r2=0.93), acute ﬂuoxetine
(n=7) ( , r2=0.92), chronic vehicle (n=9) (○, r2=0.90) and chronic ﬂuoxetine
(n=10) (•, r2=0.95) treated rats. Symbols on curves indicate the respective BP50.
(B) Linear regression of baroreﬂex curves correlating mean arterial pressure change
(Δ MAP) and heart rate response (Δ HR) of acute vehicle (○), acute ﬂuoxetine ( ),
chronic vehicle (○) and chronic ﬂuoxetine (•) treated rats. Correlation r2 values for
bradycardic regression curves were 0.81, 0.86, 0.60 and 0.90 for data of acute vehicle,
acute ﬂuoxetine, chronic vehicle, and chronic ﬂuoxetine treated rats, respectively.
Correlation r2 values for tachycardic regression curves were 0.92, 0.90, 0.89 and 0.95
for data of acute vehicle, acute ﬂuoxetine, chronic vehicle, and chronic ﬂuoxetine treated
rats, respectively. Increase or decrease in the mean arterial pressure was induced by the
i.v. infusion of phenylephrine or sodium nitroprusside, respectively.bradycardia (Fig. 2B). Analyses of tachycardiac response slopes
(acute vehicle: −1.8±0.1 bpm/mm Hg; acute ﬂuoxetine: −1.9±
0.2 bpm/mm Hg; chronic vehicle: −1.8±0.1 bpm/mm Hg; chronic
ﬂuoxetine: −1.0±0.05 bpm/mm Hg) also indicated signiﬁcant effects
of treatment regimen (F(1,30)=17, Pb0.0003) and treatment (F(1,30)=
11, Pb0.003), as well as treatment regimen×treatment interaction
(F(1,30)=17, Pb0.0003) (Fig. 2B). Post hoc analyses revealed that
ﬂuoxetine treatment for 21 days (Pb0.001), but not acute treatment
(PN0.05), signiﬁcantly decreased reﬂex tachycardia (Fig. 2B).3.3. Effect of acute or chronic ﬂuoxetine treatment on the pressor
dose–response curve for phenylephrine and depressor dose–response
curve for sodium nitroprusside
Phenylephrine, a selective α1-adrenoceptor agonist, dose-
dependently induced pressor responses in all experimental
groups (Fig. 3). Analyses of Emax of dose–response curves indicated
signiﬁcant effects of treatment regimen (F(1,30)=11, Pb0.003)
and treatment (F(1,30)=11, Pb0.003), as well as treatment regimen×
treatment interaction (F(1,30)=4, Pb0.01) (Table 3). Post hoc analyses
revealed that ﬂuoxetine treatment for 21 days (Pb0.001), but not
acute administration (PN0.05), signiﬁcantly reduced pressor response
(Fig. 3 and Table 3). There were no signiﬁcant effects on the ED50 of
the dose–response curve (F(1,30)=0, PN0.05) (Table 3).
Sodium nitroprusside, a nitric oxide donor, dose-dependently
reduced arterial pressure in all experimental groups (Fig. 3). There
were signiﬁcant effects of treatment regimen (ED50: F(1,30)=60,
Pb0.0001; Emax: F(1,30)=53, Pb0.0001) and treatment (ED50: F(1,30)=
15, Pb0.0005; Emax: F(1,30)=42, Pb0.0001), as well as treatment
regimen×treatment interaction (ED50: F(1,30)=15, Pb0.0005; Emax:
F(1,30)=42, Pb0.0001) on the ED50 and Emax of the dose–response
curve for sodium nitroprusside. Post hoc analyses indicated that
ﬂuoxetine treatment for 21 days (ED50: Pb0.001; Emax: Pb0.001), but
not acute treatment (ED50: PN0.05; Emax: PN0.05), signiﬁcantly reduced
sodium nitroprusside depressor response (Fig. 3 and Table 3).3.4. Effects of acute or chronic ﬂuoxetine treatment on cardiovascular
responses to acute restraint stress
Three-way ANOVA performed for cardiovascular responses to
acute restraint indicated signiﬁcant effects of treatment regimen
(mean arterial pressure: F(1,450)=28, Pb0.001; heart rate: F(1,450)=
37, Pb0.001), treatment (mean arterial pressure: F(3,450)=207,
Pb0.001; heart rate: F(3,450)=307, Pb0.001), and time (mean arterial
pressure: F(14,459)=46, Pb0.0001; heart rate: F(14,450)=102,
Pb0.001) (Fig. 4). There were also signiﬁcant treatment regi-
men×treatment×time interaction (mean arterial pressure: F(42,450)=
3.3, Pb0.0001; heart rate: F(42,450)=5.1, Pb0.0001). Post hoc analyses
revealed that ﬂuoxetine treatment for 21 days (mean arterial pressure:
Pb0.0001; heart rate: Pb0.0001), but not acute treatment (mean
arterial pressure: PN0.05; heart rate: PN0.05), reduced both pressor
and tachycardiac responses to acute restraint stress (Fig. 4).
Fig. 3. Changes in mean arterial pressure (ΔMAP) evoked by increasing concentrations of the selective α1-adrenoceptor agonist phenylephrine and the nitric oxide donor sodium
nitroprusside (SNP) in acute vehicle (n=8), acute ﬂuoxetine (n=7), chronic vehicle (n=9), and chronic ﬂuoxetine (n=10) treated rats. Circles represent the mean and bars the
S.E.M. *Pb0.05 compared to vehicle, two-way ANOVA followed by Bonferroni's post hoc test. Fluoxetine treatment for 21 days signiﬁcantly reduced both pressor response following
phenylephrine (Pb0.001) and depressor response following sodium nitroprusside (Pb0.001).
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It has been reported that ﬂuoxetine lowers arterial pressure in
hypertensive rats (Fuller et al., 1979). In the present study, we report
the development of mild hypertension after ﬂuoxetine treatment for
21 days in normotensive rats. To our knowledge, this is the ﬁrst
study to show an increase in arterial pressure basal levels in healthy
animals. This result corroborates with clinical reports of increased
arterial pressure associated with ﬂuoxetine treatment in elderly and
cardiac patients (Hussein and Kaufman, 1994; Roose et al., 1998).
However, the increase in arterial pressure contrasts with previous
preclinical studies showing that ﬂuoxetine treatment for 4, 16 or
28 days did not affect cardiovascular basal parameters in rats (Grippo
et al., 2006; Mofﬁtt and Johnson, 2004). The reasons for the discrep-
ancy are not clear. Nevertheless, it is interesting to note that basal
values of mean arterial pressure reported in these previous studies
were higher (110–130 mm Hg) than those observed in the control
animals of the present study (~100 mm Hg) (Grippo et al., 2006;
Mofﬁtt and Johnson, 2004). Moreover, in the previous studies cardio-
vascular activity was measured 24 h after the last injection of ﬂuoxe-
tine. This difference in experimental protocol may be relevant, since
plasma ﬂuoxetine levels decrease 90% 8 h after administration (Liu
et al., 2005). In our protocol, cardiovascular activity was investigated
30 min after the 21st injection, thus addressing effects of ﬂuoxetine
treatment in cardiovascular functions during chronic treatment.
Since the ﬂuoxetine metabolite norﬂuoxetine is still present in the
plasma 48 h after treatment (Durand et al., 1999), our results, together
with previous data that investigated cardiovascular activity 24 h after
the last injection, suggest that ﬂuoxetine, and not its metabolite, is
important in cardiovascular consequences of chronic ﬂuoxetine
treatment.
The mechanism by which chronic ﬂuoxetine treatment might
induce an increase in arterial pressure is unknown. Our data showed
that either acute or chronic ﬂuoxetine treatment did not affect resting
heart rate, thus suggesting that heart rate changes do not mediate theTable 3
Maximal effect (Emax) and ED50 values for phenylephrine (phenyl) and sodium nitro-
prusside (SNP) dose–response curves obtained from acute vehicle (n=8), acute ﬂuox-
etine (n=7), chronic vehicle (n=9) and chronic ﬂuoxetine (n=10) rats. Value is the
mean±S.E.M.
Group Phenyl SNP
ED50 Emaxl ED50 Emax
Acute vehicle 0.6±0.03 36±3 1.1±0.05 −33±1
Acute ﬂuoxetine 0.7±0.04 33±3 1.1±0.02 −33±2
Chronic vehicle 0.7±0.03 33±1 1.0±0.05 −32±1
Chronic ﬂuoxetine 0.6±0.04 21±2a 0.8±0.03* −16±1a
a Pb0.05 vs chronic vehicle, two-way ANOVA followed by Bonferroni's post hoc test.elevation of arterial pressure in ﬂuoxetine-treated rats. Similarly,
previous studies reported that resting heart rate was not affected by
chronic ﬂuoxetine treatment in rats (Alper, 1992; Grippo et al.,
2006; Mofﬁtt and Johnson, 2004).
An impaired baroreﬂex control of heart rate has been associated
with hypertension in humans and animal models of hypertension
(Grassi et al., 2006; Irigoyen and Krieger, 1998). Acute ﬂuoxetine
treatment did not affect baroreﬂex control of heart rate. However,
we have observed that tachycardiac responses to blood pressure
decreases caused by intravenous infusion of sodium nitroprusside
were inhibited, whereas bradycardiac responses evoked by blood
pressure increases caused by intravenous infusion of phenylephrine
were enhanced after ﬂuoxetine treatment for 21 days. It was previ-
ously reported that ﬂuoxetine treatment for 4, 16 or 27 days did not
affect cardiac baroreﬂex response (Alper, 1992; Mofﬁtt and Johnson,Fig. 4. Time-course of mean arterial pressure (ΔMAP) and heart rate (ΔHR) changes
during acute restraint stress in acute vehicle (n=8), acute ﬂuoxetine (n=7), chronic
vehicle (n=9), and chronic ﬂuoxetine (n=10) treated rats. Circles represent the
mean and bars the S.E.M. *Pb0.05 vs chronic vehicle, three-way ANOVA followed by
Bonferroni's post hoc test. Fluoxetine treatment for 21 days signiﬁcantly reduced both
the pressor (Pb0.001) and tachycardic (Pb0.001) response to acute restraint stress.
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explain the discrepancy, since in these previous studies baroreﬂex
activity was studied 24 h after the last injection of ﬂuoxetine. The
baroreﬂex bradycardiac and tachycardiac responses are mainly medi-
ated by cardiac parasympathetic and sympathetic stimulation,
respectively (Head and McCarty, 1987). Consequently, our data sup-
port the idea that chronic ﬂuoxetine treatment inhibits the sympathetic
component of baroreﬂex activity and facilitates the parasympathetic
component of baroreﬂex activity. Considering that the impairment of
the baroreﬂex control of heart rate in hypertension extends to the
tachycardiac response evoked during baroreﬂex unloading (Grassi
et al., 2006), the decreased tachycardiac baroreﬂex response could
play a role in the elevation of arterial pressure in ﬂuoxetine-treated
rats. However, present results do not link the change in bradycardiac
baroreﬂex response following ﬂuoxetine treatment with the alteration
of arterial pressure.
Several mechanisms may explain the effect of ﬂuoxetine on barore-
ﬂex activity. It was previously reported that ﬂuoxetine treatment for
21 days increased the number of cells showing Fos-like immunoreactivi-
ty, a marker of neuronal activation, in several central nervous system
areas involved in control of autonomic activity (Lino-de-Oliveira et al.,
2001). Considering that these structures are involved in the cardiac baror-
eﬂex response, the central action of ﬂuoxetine could mediate the change
in baroreﬂex activity. In vitro studies indicated that ﬂuoxetine inhibited
L-type Ca2+ channels in cardiac cells (Park et al., 1999), thus suggesting
that this drug could play an important role in reducing HR, cardiac
contractility, and atrio-ventricular conduction. Therefore, although
chronic ﬂuoxetine treatment does not affect resting heart rate, a direct
action of the drug in the heart could facilitate reﬂex bradicardia and
inhibit tachycardiac response.
In opposition to tricyclic antidepressants, SSRIs have little afﬁnity
for α-adrenoceptors (Wong et al., 1983). Therefore, reduction in
pressor response to phenylephrine reported in the present study
after chronic ﬂuoxetine treatment is not associated with blockade of
vascular α1-adrenoceptors by ﬂuoxetine. In fact, there is a negative
correlation between the pressor response to phenylephrine and
baroreﬂex control of heart rate (Goldstein, 1983; Gordon et al.,
1981). Thus, the decreased responsiveness to phenylephrine could
be related to the enhanced baroreﬂex activity. Nevertheless, other
ﬂuoxetine effects may also explain the reduced phenylephrine
responsiveness. The reduction in phenylephrine response corrobo-
rates with in vitro results reporting that ﬂuoxetine antagonizes arteri-
al constrictions to norepinephrine and serotonin (Pacher et al., 1999;
Ungvari et al., 1999). It has been documented that ﬂuoxetine blocks
entry of Ca2+ into arteriolar smooth muscle cells, most likely by inhi-
biting L-type Ca2+ channels (Pacher et al., 1999; Ungvari et al., 2000).
It is interesting to note that tricyclic antidepressants also produce
relaxation in vascular smooth muscle cells (Vila et al., 1999), probably
by inhibiting Ca2+ entry (Auguet et al., 1986). On the basis of these re-
sults, a smooth muscle-relaxing effect, by interfering with Ca2+-entry,
seems to be a general characteristic of themonoamine-uptake inhibitor
compounds.
Impairment of vascular relaxation responses due to chronic ﬂuoxe-
tine treatment may be responsible, at least in part, for the development
of ﬂuoxetine-induced hypertension. In the present work, the hypoten-
sive response induced by sodium nitroprusside was decreased after ﬂu-
oxetine treatment for 21 days. It has been proposed that hypertension is
associated with impaired endothelial function, which can be explained
by a decrease in nitric oxide generation, or by an enhanced inactivation
of nitric oxide after its release from endothelial cells (Panza et al., 1993).
Moreover, other mechanisms may be postulated, including altered
guanylate cyclase activity or other down-stream nitric oxide pathways.
Although reduction of intracellular calcium in smoothmuscle cells is an
important mechanism by which nitric oxide dilates blood vessels
(Akata, 2007), a ﬂuoxetine-mediated decrease of vascular reactivity to
sodium nitroprusside seems not to be related to ﬂuoxetine inﬂuenceon vascular L-type Ca2+ channels, since inhibition of this channel
augments the relaxing capacity of nitric oxide (Van Hove et al., 2009).
Cardiovascular changes are part of the physiological response
during aversive stimuli, and they are aimed at maintaining homeosta-
sis (Ulrich-Lai and Herman, 2009). In the present study, ﬂuoxetine
treatment for 21 days reduced cardiovascular responses to acute
restraint stress. Present results contrast with those of Grippo et al.
(2006), who reported an increased tachycardiac response to air-jet
stress after ﬂuoxetine treatment for 28 days. Since differences in car-
diovascular responses to restraint stress and air-jet stress have been
reported (McDougall et al., 2005), the use of different stressors may
explain the discrepancy. It has been proposed that a gating mecha-
nism is operative in the central nervous system that determines the
cardiovascular response to aversive stimuli (Dampney et al., 2008;
Ulrich-Lai and Herman, 2009). Fluoxetine treatment induces changes
in the restraint-induced increase in Fos-like immunoreactivity in several
areas of the central nervous system involved in autonomic control
(Lino-de-Oliveira et al., 2001), suggesting that a change in the pattern of
central activation could mediate the ﬂuoxetine inﬂuence on cardiovascu-
lar responses to restraint stress.
In summary, the present results provide an advance in our under-
standing of the cardiovascular effects of ﬂuoxetine. Our results show
the development of mild hypertension after ﬂuoxetine treatment for
21 days. Alterations in baroreﬂex activity and impairment of vascular
relaxation responses to vasodilator agents may be responsible, at
least in part, for the development of ﬂuoxetine-induced hypertension.
However, mechanisms involved in the mild hypertension following
ﬂuoxetine treatment deserve further investigation. The present
study also shows that chronic ﬂuoxetine treatment alters the pressor
responsiveness to vasoactive agents, further indicating that the car-
diovascular system counteracts the effects induced by ﬂuoxetine
using mechanisms involved in the maintenance of vascular tonus.
Finally, ﬂuoxetine treatment for 21 days reduced cardiovascular
responses to restraint-stress, thus suggesting that ﬂuoxetine may
affect adaptation under conditions of stress. Clinicians should be
more vigilant about these potential adverse reactions, especially in
patients with cardiovascular disorders. The SSRIs have achieved such
phenomenal usage mainly because of a favorable safety and tolerability
proﬁle. However, it is important for clinicians to have an awareness of
the adverse effects and not assume that SSRIs are devoid of potential
medical complications.
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